Following successful completion of the Phase 1 challenge awarded to ImmuONE by NC3Rs, we were announced as the winners for the Phase 2 challenge in January 2022. Sponsored by Unilever and AstraZeneca, the project aims to establish and develop in vitro OECD test guideline assays; free from animal-derived products and demonstrate their equivalence and superiority to current strategies. Once optimised, these technologies will progress to commercially ready, human relevant, animal-free bioassays with the view of gaining regulatory acceptance.
This session highlighted where prediction fails today, the mechanistic gaps that limit current approaches, and how human NAMs can help close that gap. It also emphasised the key insights teams need to move from reactive findings to more proactive, informed decision-making.
To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues. This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.
In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.